[New antiplatelet drugs].
Platelet-aggregation inhibitors are the cornerstone of the treatment and prevention of atherothrombotic events. Long limited to aspirin alone, new drugs have appeared in the past two decades. But only very recently have new targets been developed. The synergy of their mechanisms of action now makes it possible to obtain ever stronger inhibition of platelet aggregation.
Bellemain
Anne
A
Institut de cardiologie, Unité Inserm 856, Hôpital Pitié-Salpêtrière F-75013 Paris, France.
Collet
Jean-Philippe
JP
Montalescot
Gilles
G
D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*
D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors